Affiliation:
1. Hematopathology, Department of Pathology and Laboratory Medicine Children's Hospital Los Angeles Los Angeles California USA
2. Keck School of Medicine of University of Southern California Los Angeles California USA
3. Miller School of Medicine of University of Miami Miami Florida USA
4. Biostatistics Core, The Saban Research Institute Children's Hospital Los Angeles Los Angeles California USA
5. Cancer and Blood Disease Institute Children's Hospital Los Angeles Los Angeles California USA
6. Cytogenomics, Center for Personalized Medicine, Department of Pathology and Laboratory Medicine Children's Hospital Los Angeles Los Angeles California USA
Abstract
AbstractBackgroundCompared to other ethnicities, Hispanics/Latinos (H/L) have a high incidence of acute lymphoblastic leukemia (ALL), enrichment of unfavorable ALL genetic subtypes, and worse outcomes, even after correcting for socioeconomic factors. We previously demonstrated increased incidence of the high‐risk genetic drivers IKZF1 deletion and IGH::CRLF2 rearrangement in H/L compared to non‐H/L children with B‐ALL. Here in an expanded pediatric cohort, we sought to identify novel genetic drivers and secondary genetic alterations in B‐ALL associated with H/L ethnicity.ProcedureComprehensive clinicopathologic data from patients with B‐ALL treated from 2016 to 2020 were analyzed. Subtype was determined from karyotype, fluorescence in situ hybridization (FISH), chromosome microarray (CMA), and our next‐generation sequencing (NGS) panel (OncoKids). Non‐driver genetic variants were also examined. p‐Values less than .05 (Fisher's exact test) were considered significant.ResultsAmong patients with B‐ALL at diagnosis (n = 273), H/L patients (189, 69.2%) were older (p = .018), more likely to present with CNS2 or CNS3 disease (p = .004), and NCI high‐risk ALL (p = .014) compared to non‐H/L patients. Higher incidence of IGH::CRLF2 rearrangement (B‐ALL, BCR::ABL1‐like, unfavorable; p = .016) and lower incidence of ETV6::RUNX1 rearrangement (favorable, p = .02) were also associated with H/L ethnicity. Among secondary (non‐subtype‐defining) genetic variants, B‐ALL in H/L was associated with IKFZ1 deletion alone (p = .001) or with IGH::CRLF2 rearrangement (p = .003). The IKZF1PLUS profile (IKZF1 deletion plus CDKN2A/2Bdel, PAX5del, or P2RY8::CRLF2 rearrangement without DUX4 rearrangement) was identified as a novel high‐risk feature enriched in H/L patients (p = .001).ConclusionsOur study shows enrichment of high‐risk genetic variants in H/L B‐ALL and raises consideration for novel therapeutic targets.
Funder
Children's Hospital Los Angeles
Reference44 articles.
1. B‐lymphoblastic leukemia/lymphoma NOS.National Cancer Institute (NCI) SEER.
2. Cancer stat facts: leukemia — acute lymphocytic leukemia (ALL).SEER. Accessed July 17 2023.https://seer.cancer.gov/statfacts/html/alyl.html
3. Acute Lymphoblastic Leukemia in Adolescents and Young Adults
4. Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
5. American Cancer Society.Cancer facts and figures for Hispanics/Latinos 2018–20.American Cancer Society. Accessed: August 21 2023. chrome‐extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.cancer.org/content/dam/cancer‐org/research/cancer‐facts‐and‐statistics/cancer‐facts‐and‐figures‐for‐hispanics‐and‐latinos/cancer‐facts‐and‐figures‐for‐hispanics‐and‐latinos‐2018‐2020.pdf